The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
LOXL2—A New Target in Antifibrogenic Therapy?
Open accessAbstract
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [131]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309 · cited 2×
“Expression levels of LOXL2 were markedly increased in matched adjacent non-tumor tissue compared with levels in tumor tissue samples, and this difference gradually increased with higher histological grade and more advanced hepatocellular tumors [39].”
BackgroundRetractedBataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266 · cited 1×
“In a multicenter randomized placebo-controlled trial involving 651 patients with HBV cirrhosis [27], lamivudine decreased the risk of severe liver complications (7.”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310 · cited 6×
“The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action (inactive macrophage Ly6Clow) [6,23].”
BackgroundInfluentialRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Research works printed but not linked: 6
- Cabezas, 2017, Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral, Hepatology, 66, 218A
- Bosch, 2015, Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), Hepatology, 62, 120A
- Afdha, 2015, Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C, Hepatology, 62, 121A
- Bourliere, 2015, Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir/sofosbuvir (LDV/SOF)-based therapy, Hepatology, 62, 123A
- Puente, 2019, Influence of the metabolic syndrome on fibrosis regression regulated by LOXL2 after sustained virologycal response, Gastroenterol. Hepatol., 42, 123
- Tatal, 2013, Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase like 2, appears safe and well tolerated in patients with liver disease of diverse etiology, J. Hepatol., 58, S409
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“For example, LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131] .”
BackgroundLysyl oxidases: from enzyme activity to extracellular matrix cross-links
Vallet, S. D., & Ricard-Blum, S. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180050 · Cited by 335
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
“ECM synthesis and degradation, and activities of ECM stabilizing cross-linking enzymes, increase with accumulation of fi broblasts and myo fi broblasts, and progression of fi brotic disease [37 – 39].”
BackgroundChen, W., Yang, A., Jia, J., Popov, Y. V., Schuppan, D., & You, H. (2020) · Hepatology · doi:10.1002/hep.31236 · Cited by 284
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 158
Metadata
- Authors
- Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J.
- Affiliations
- Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain
- Universidad de Cantabria (ES)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1634
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480111
- OpenAlex
- W2933665664
- Cited by
- 79
- References
- 58
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 13 · 2019: 6
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- LOXL2, liver fibrosis, antifibrotic therapy, liver cirrhosis, extracellular matrix, collagen deposition, hepatic stellate cells, Kupffer cells, monoclonal antibodies, fibrosis reversibility, portal pressure
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Protein-Lysine 6-Oxidase, Models, Biological, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LOXL2—A New Target in Antifibrogenic Therapy? https://app.cochat.ai/papers/10.3390/ijms20071634
- The paper
- Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019). LOXL2—A New Target in Antifibrogenic Therapy? International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20071634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.